ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL231779
CHEMBL231779
Compound Name APIXABAN
ChEMBL Synonyms BMS-562247-01 | APIXABAN | ELIQUIS | BMS-562247
Max Phase 4 (Approved)
Trade Names ELIQUIS
Molecular Formula C25H25N5O4

Additional synonyms for CHEMBL231779 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES COc1ccc(cc1)n2nc(C(=O)N)c3CCN(C(=O)c23)c4ccc(cc4)N5CCCCC5=O
Standard InChI InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27 ...
Download InChI
Standard InChI Key QNZCBYKSOIHPEH-UHFFFAOYSA-N

Sources

  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL231779

Molecule Features

CHEMBL231779 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Coagulation factor X inhibitor Coagulation factor X DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease1ClinicalTrials
ThrombosisD013927HP:0004419Recurrent thrombophlebitis4ATC
Venous ThrombosisD020246EFO:0003907deep vein thrombosis4ClinicalTrials
DailyMed
DailyMed
LymphomaD008223EFO:0000574lymphoma3ClinicalTrials
Venous ThrombosisD020246HP:0004936Venous thrombosis4ClinicalTrials
Anemia, Sickle CellD000755Orphanet:232Sickle cell anemia3ClinicalTrials
Aortic Valve StenosisD001024EFO:0000266aortic stenosis3ClinicalTrials
HemorrhageD006470MP:0001914hemorrhage2ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia3ClinicalTrials
Acute Coronary SyndromeD054058EFO:0005672acute coronary syndrome3ClinicalTrials
Atrial FlutterD001282EFO:0003911atrial flutter3ClinicalTrials
Renal InsufficiencyD0514373ClinicalTrials
StrokeD020521EFO:0000712stroke4ClinicalTrials
DailyMed
DailyMed
Venous ThromboembolismD054556EFO:0004286venous thromboembolism3ClinicalTrials
Atrial FibrillationD001281EFO:0000275atrial fibrillation4ClinicalTrials
DailyMed
DailyMed
Pulmonary EmbolismD011655EFO:0003827pulmonary embolism4ClinicalTrials
DailyMed
DailyMed

Clinical Data

ClinicalTrials.gov APIXABAN
The Cochrane Collaboration APIXABAN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL231779. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL244 Coagulation factor X Homo sapiens 1.000
CHEMBL5062 Coagulation factor X Oryctolagus cuniculus 0.993
CHEMBL1963 Thyroid stimulating hormone receptor Homo sapiens 0.763
CHEMBL5514 Huntingtin Homo sapiens 0.306
CHEMBL1293231 Nuclear receptor ROR-gamma Mus musculus 0.270
CHEMBL2026 Beta-lactamase AmpC Escherichia coli K-12 0.230



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL244 Coagulation factor X Homo sapiens 1.000
CHEMBL5062 Coagulation factor X Oryctolagus cuniculus 0.949
CHEMBL2026 Beta-lactamase AmpC Escherichia coli K-12 0.419
CHEMBL3577 Aldehyde dehydrogenase 1A1 Homo sapiens 0.397
CHEMBL1963 Thyroid stimulating hormone receptor Homo sapiens 0.389
CHEMBL1293277 Niemann-Pick C1 protein Homo sapiens 0.248
CHEMBL4159 Endoplasmic reticulum-associated amyloid beta-peptide-binding protein Homo sapiens 0.222

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
459.5 459.1907 2.7 5 110.76 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 1 0 9 2 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- .81 4.66 4.66 3 34 0.63

Structural Alerts

There are no structural alerts for CHEMBL231779

Compound Cross References

ATC B - BLOOD AND BLOOD FORMING ORGANS
B01 - ANTITHROMBOTIC AGENTS
B01A - ANTITHROMBOTIC AGENTS
B01AF - Direct factor Xa inhibitors
B01AF02 - apixaban

ChemSpider ChemSpider:QNZCBYKSOIHPEH-UHFFFAOYSA-N
DailyMed apixaban
PubChem SID: 174006823
Wikipedia Apixaban

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL231779



ACToR 503612-47-3
BindingDB 19023
Brenda 3564 85842
ChEBI 72296
ChemicalBook CB51508586
DrugBank DB06605
DrugCentral 4298
eMolecules 32278100
EPA CompTox Dashboard DTXSID80436500
FDA SRS 3Z9Y7UWC1J
Guide to Pharmacology 6390
IBM Patent System 6CFD8A8A2762E0EF1DC548DA88E04E7C
LINCS LSM-45660
MolPort MolPort-006-170-153
Nikkaji J2.566.952E
PDBe GG2
PharmGKB PA166163740
PubChem 10182969
PubChem: Drugs of the Future 56310620
PubChem: Thomson Pharma 15178464
Selleck Apixaban(BMS-562247-01)
SureChEMBL SCHEMBL118023
ZINC ZINC000011677837

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/QNZCBYKSOIHPEH-UHFFFAOYSA-N spacer
spacer